China’s NMPA conditionally approves Boehringer’s tablets for NSCLC
China's National Medical Products Administration (NMPA) has granted conditional approval to Boehringer Ingelheim's Hernexeos (zongertinib tablets), for use as a…
Respiratory
-
-
FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration (FDA) for izalontamab…
-
Insmed wins FDA approval for future blockbuster Brinsupri
Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1)…
-
Fosun and Expedition make $645m licensing deal for respiratory drug
Fosun Pharma's subsidiary, Fosun Pharma Industrial, has entered a licence agreement to grant ex-China rights for its experimental respiratory drug,…
-
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…
-
Vertex and NHS England agree reimbursement for Alyftrek
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). This follows…
-
Viatris gains China approval for Yupelri to treat COPD
Theravance Biopharma’s partner Viatris has received China's National Medical Products Administration (NMPA) approval for Yupelri (revefenacin) inhalation solution for maintenance…
-
Zambon gains Chinese regulatory authority approval for Fluimucil IV
Zambon Pharma has received approval from Chinese regulatory authorities and launched Fluimucil (N-acetylcysteine) intravenous (IV) formulation in the country. The…
-
Mosanna Therapeutics gains $80m to advance OSA nasal spray
Mosanna Therapeutics has secured $80m in a Series A funding round to advance a new nighttime nasal spray for obstructive…
-
MSD receives FDA approval for Enflonsia to prevent RSV
MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower…
